Donald Trump’s decision to repeal existing measures unlikely to dissuade investors from engaging with pharmaceutical companies.
Investors emphasise the need for companies to increase voluntary licensing of medicines, after new benchmark report reveals slowdown.
Though a growing cohort of investors is prepared to fight for equal access to medicine, the absence of strict pricing regulation remains...
Investors urged to flag financial and systemic risks of anti-microbial resistance and to support collaborative engagement initiatives to ensure influence on policy.
Shareholder proposals at 2023 AGMs seek clarity on patent practices by large US drug companies, ensuring innovations are driven by science rather...
Subscribe to our free weekly newsletter below and never miss a story.